Morningstar - Truist Financial Corporation (BBT) Slowing Underlying Fee Growth for BBT; Future Gains From SunTrust Merger Remain Key

Report

Morningstar

Eric Compton

EUR 100.00 For Business Accounts Only

Slowing Underlying Fee Growth for BB&T; Future Gains From SunTrust Merger Remain Key

Narrow-moat BB&T turned in an OK first quarter. Adjusted return on average assets was 1.55%, while adjusted return on average tangible equity was 19.86%, both roughly in the range we have seen recently for the bank. Adjusted earnings per share were $1.05 for the quarter, up 8.2%, while preprovision net revenue was up 3%. The bankâ€™s overall expenses were affected in the quarter by extra items related to the pending merger with SunTrust; however, BB&T did also call out extra marketing expe...

22/04/2019 14 EN

Underlying

Truist Financial Corporation

BB&T is a financial holding company. Through its bank subsidiary, Branch Banking and Trust Company, the company provides banking services to individuals, businesses and municipalities. The company provides loans and lease financing, including commercial and residential mortgages; permanent commercial real estate financing arrangements; loan servicing for third-party investors; direct consumer finance loans to individuals; credit card lending; automobile financing; and equipment financing. The company also provides other services, including deposits; discount and brokerage, annuities and mutual funds; life insurance, property and casualty insurance, health insurance and commercial general liability insurance.

See profile

US0549371070 United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Eric Compton

Other Reports on these Companies

MarketLine

Synovus Financial Corp - Company Profile and SWOT Analysis

Summary Synovus Financial Corp - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Synovus Financial Corp (Synovus) is a bank-holding company, which provides retail, commercial, and corporate banking; and other related financial services through its subsidiaries. It offers accounts and deposit services such as, checking, savings, corporate of deposits, and money market accoun...

EUR 149.70

July 20, 2024 July 20, 2024 1 EN

MarketLine

Synovus Financial Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances

Summary Marketline's Synovus Financial Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Synovus Financial Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity un...

EUR 299.39

September 29, 2023 September 29, 2023 1 EN

DBRS Morningstar

DBRS Morningstar: Federal Reserve Stress Tests Again Highlight CRE Risk

This commentary reviews the Federal Reserve's annual stress test with a primary focus on commercial real estate (CRE). Key highlights include: •Positively, all 23 banks in this year's iteration cleared the Federal Reserve stress tests and would all be able to continue to lend supporting the economy. •This year's stress test included heightened stress scenarios, especially around CRE. Next to credit cards, CRE had the highest loss levels of any asset class. •Preliminary stress capital buffers (SCB) have been released by some banks ranging from 2.50%.to 5.5%. “Overall, projected CRE loss rates...

July 10, 2023 July 10, 2023 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Slowing Underlying Fee Growth for BB&T; Future Gains From SunTrust Merger Remain Key

Synovus Financial Corp - Company Profile and SWOT Analysis

Synovus Financial Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances

DBRS Morningstar: Federal Reserve Stress Tests Again Highlight CRE Risk

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe